Eye disease biopharmaceutical company: EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was founded in 1987, formerly known as pSivida Corp., changed to its current name in March 2018, headquartered in Watertown, Massachusetts, USA, with 22 full-time employees, is a specialty biopharmaceutical company , Engaged in the development and commercialization of medical products related to ophthalmic indications with high medical needs to help improve the lives of patients with eye diseases.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (EYPT):

EyePoint Pharmaceuticals has developed three FDA-approved ophthalmic sustained-release treatment methods, including: DEXYCU (dexamethasone intraocular suspension), which is used as a single intraocular dose for postoperative inflammation at the end of eye surgery; ILUVIEN (fluocinolone acetonide) Intravitreal implant), a microimplant for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

EyePoint Pharmaceutical’s main product candidate is Duraset (fluocinolone acetonide intravitreal implant), a miniature implant used to treat non-infectious uveitis that affects the posterior segment of the eye.

In addition, EyePoint Pharmaceuticals’ pre-clinical development plan focuses on using its core Duraset platform technology to provide drugs for the treatment of wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

EyePoint Pharmaceuticals, Inc. signed a license agreement for Retisert products with Bausch and Lomb; signed a license agreement with Alimera for the intuitive application of ILUVIEN equipment; and signed a cooperation agreement with Pfizer for the supply of latanoprost Duraset equipment.

Notify of
Inline Feedbacks
View all Intels

Biopharmaceutical company: Opiant Pharmaceuticals, Inc. (OPNT)

Energy retail & oil and gas exploration company: Genie Energy (GNE) (2011)